1% OPA-15406 Ointment

DRUG4 trials

Sponsors

Otsuka Pharmaceutical Co., Ltd., Otsuka Beijing Research Institute

Conditions

Atopic DermatitisAtopic Dermatitis (AD)

Phase 1

A Phase 1 Trial of OPA-15406 Ointment in Healthy Adult Male Subjects

CompletedNCT02334787

Otsuka Pharmaceutical Co., Ltd.Atopic Dermatitis

Start: 2015-01-31End: 2015-02-28Updated: 2016-10-03

Phase 3

Long-term Trial of OPA-15406 Ointment in Adult and Pediatric Patients With Atopic Dermatitis

CompletedNCT03961529

Otsuka Pharmaceutical Co., Ltd.Atopic Dermatitis

Start: 2019-05-14End: 2020-11-11Updated: 2021-11-19

To Demonstrate the Superiority of IMP (0.3% and 1% OPA-15406 Ointment) Versus the Vehicle in Pediatric Patients with AD

CompletedNCT05650320

Otsuka Beijing Research InstituteAtopic Dermatitis (AD)

Start: 2023-02-17End: 2025-01-15Updated: 2025-03-25

To Demonstrate the Superiority of IMP (1% OPA-15406 Ointment) to the Vehicle in Adult Patients With AD

CompletedNCT05667623

Otsuka Beijing Research InstituteAtopic Dermatitis (AD)

Start: 2023-02-06End: 2024-11-29Updated: 2025-08-29

Related Papers

Difamilast Ointment in Japanese Adult and Pediatric Patients with Atopic Dermatitis: A Phase III, Long-Term, Open-Label Study

Dermatology and Therapy2022-06-1821 citations